Several risk factors for the spot sign have been identified, including larger initial hematoma volume, anticoagulation, early presentation, and APOE ε2 allele, suggesting that underlying features of the brain or the blood vessels may impact its development. 3 Of note, APOE ε2 is associated with spot sign in lobar and not deep ICH. 4 However, whether there are other factors that influence the spot sign in a location-specific manner is not known. We therefore investigated whether clinical or imaging characteristics are associated with spot sign in a location-specific manner, using ICH location as a surrogate for arteriolosclerosis-and cerebral amyloid angiopathy-related ICH.
P rimary intracerebral hemorrhage (ICH) occurs as the acute manifestation of chronic small vessel disease. The most common pathological findings are cerebral amyloid angiopathy for lobar ICH and arteriolosclerosis for nonlobar or deep ICH. 1 Although deep and lobar ICH share several risk factors, these conditions are generally associated with different chronic small vessel diseases. 1 The computed tomography angiography (CTA) spot sign is a strong predictor of hematoma expansion and clinical outcome.
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consent was obtained from all participants or their next of kin, or consent was waived by a protocol-specific allowance. Inclusion criteria comprised primary supratentorial ICH and CTA performed within 72 hours of symptom onset. Exclusion criteria were infratentorial ICH, multiple hemorrhages, primary intraventricular hemorrhage, and secondary causes of ICH. ICH location was determined on admission computed tomography according to published methods. 4 Hemorrhages involving both lobar and deep regions (n=5) were excluded. CTAs were reviewed by 2 independent, blinded readers. 6 Hematoma volumes were measured using Analyze 10.0 (Mayo Clinic, Rochester, MN) software. 6 Hematoma expansion defined as absolute growth >6 mL or a relative increase >33% as compared with the baseline computed tomography was evaluated in subjects with an available follow-up computed tomography. 7 We performed univariable and multivariable regression, stratified by ICH location. Covariates with P<0.05 in univariable analyses were entered into the model and backward eliminated to P<0.2. Collinearity was assessed through the variance inflation factor. Statistical analyses were performed using R version 3.0.1 (R Foundation for Statistical Computing) with significance threshold P<0.05.
Results
Of the initial 920 patients, 741 were included in final analysis ( Figure) . Cohort characteristics are presented in Table I in the online-only Data Supplement. Subjects excluded because of lack of CTA, or CTA performed after 72 hours (19%) had similar characteristics to included individuals (Table II in 
Spot Sign in Deep ICH
Predictors of spot sign in deep ICH identified through univariable analysis were male sex, atrial fibrillation, antiplatelet therapy, warfarin, international normalized ratio, intraventricular hemorrhage, larger baseline ICH volume, and shorter time to CTA (Table III in 
Spot Sign in Lobar ICH
In univariable analysis, male sex, coronary artery disease, atrial fibrillation, antiplatelet therapy, warfarin, systolic blood pressure, international normalized ratio, intraventricular hemorrhage, larger baseline ICH volume, and time to CTA were associated with spot sign presence (Table III in the onlineonly Data Supplement). After adjustment, an independent association with spot sign was found for warfarin (OR, 3.95; P<0.001) and baseline ICH volume (OR, 1.20, per 10 mL increase; P<0.001) ( Table 2) .
Spot Sign and Hematoma Expansion
Follow-up computed tomography was available in 568 (69%) subjects. As expected, spot sign was a strong predictor of hematoma expansion in both deep (OR, 3.95; P<0.001) and lobar ICH (OR, 6.80; P<0.001). After adjusting for age, sex, warfarin, and ICH volume, the spot sign remained associated with hematoma expansion in both deep (OR, 3.20; P=0.002) and lobar ICH (OR, 5.38; P<0.001).
Discussion
This study identifies risk factors for the presence of the spot sign in each of the 2 ICH subtypes: arteriolosclerosis-and cerebral amyloid angiopathy-related ICH. These results suggest that the underlying pathophysiology of the spot sign shares common features across different cerebral vasculopathies.
Anticoagulant therapy and baseline hematoma volume have been consistently associated with the spot sign, 8 and this analysis confirmed these associations in both ICH subtypes. Patients with larger hematoma volumes are more likely to have prolonged bleeding, irrespective of the underlying mechanisms of vascular damage. The same holds true for anticoagulation, 
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although the effect may be more pronounced in lobar ICH. The association of shorter time to CTA and spot sign only in deep ICH is likely reflective of more pronounced symptoms in these patients, as active bleeding and subsequent expansion lead to more rapid deterioration and consequently earlier presentation. Our study is limited by the fact that as an observational study, not all patients underwent CTA, and by using one definition of the spot sign, and the limited ability to assess the clinical outcomes associated with hematoma expansion according to ICH location.
In conclusion, baseline ICH volume and anticoagulation treatment are shared risk factors between deep and lobar ICH, suggesting that spot sign occurring in ICH caused by different disease processes share common features.
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Clinical data
Demographic data, past medical history, medication use, alcohol and tobacco use, and time of symptom onset were collected through chart review and interviews with patients or their surrogates. Hospital records were reviewed for admission systolic and diastolic blood pressure, Glasgow Coma Scale score, blood glucose, and international normalized ratio (INR) measurements, and time from symptom onset to baseline CTA.
Imaging analysis
ICH location was determined based on admission CT by study neurologists or neuroradiologists blinded to clinical data. Lobar hemorrhage was defined as ICH originating in the cortex or cortico-subcortical junction. Deep ICH was defined as hemorrhage exclusively involving the thalamus, basal ganglia, internal capsule, or deep periventricular white matter.
